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Abstract
Background: Fluoxetine and olanzapine combination therapy is rapidly becoming an effective
strategy for managing symptoms of treatment-resistant depression. Determining drug-drug
interactions, drug metabolism and pharmacokinetics is of particular interest for revealing potential
liabilities associated with drug augmentation in special patient populations. In the current studies,
we chronically administered fluoxetine and olanzapine in non-stressed rats to extend our previous
findings regarding body weight dynamics.
Results:  Chronic fluoxetine (10 mg/kg) and olanzapine (5 mg/kg and 0.5 mg/kg) treatment
decreased weight gain irrespective of olanzapine dosing. At the 10 mg/kg and 5 mg/kg dose,
respectively, fluoxetine and olanzapine also significantly reduced food and water consumption. This
pharmacodynamic event-related effect, however, was not observed at the 10 mg/kg and 0.5 mg/kg
dosing paradigm suggesting differences in tolerability rates as a function of olanzapine dose. The
decrease in weight gain was not associated with apparent changes in glucose metabolism as vehicle-
and drug-treated rats showed undistinguishable serum glucose levels. The combination of
fluoxetine and olanzapine in rats yielded drug plasma concentrations that fell within an expected
therapeutic range for these drugs in psychiatric patients.
Conclusions: These data suggest that fluoxetine and olanzapine treatment decreases weight gain
in rats; a pharmacodynamic event-related effect that differs considerably from what is observed in
the clinical condition. The possibility of mismatched models regarding body weight changes during
drug augmentation therapy should be seriously considered.
Background
Treatment-resistant depression is a serious issue in psychi-
atry as a significant number of affected individuals show
an inadequate response to single antidepressant therapy.
An emerging strategy to achieve maximum mood stabili-
zation for treatment-resistant depression, bipolar illness
and depression with psychotic features is the augmenta-
tion of fluoxetine (Prozac) with novel anti-psychotic
agents such as olanzapine (Zyprexa). Indeed, a number of
clinical trials have suggested that such an augmentation
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strategy offers superior efficacy for treating resistant major
depression when compared with either fluoxetine or olan-
zapine alone [1-3]. Despite the apparent clinical benefits
of this drug strategy, little is known about the mechanisms
by which fluoxetine plus olanzapine actually function to
relieve depression. The limited literature on this issue sug-
gests that drug augmentation therapy, at least in the rat
brain, is likely to be more complicated and perhaps more
indirect than a simplistic version of fluoxetine or olanza-
pine would imply [4-7]. For instance, whereas fluoxetine
and olanzapine alone activate several signaling pathways
involved in cell survival and plasticity [8-10], drug aug-
mentation therapy reduces the levels of certain transcrip-
tion factors (e.g., cAMP response element binding protein
and FOS-like proteins) implicated in the chemical cir-
cuitry (e.g., prefrontal cortex and hippocampus) underly-
ing emotional behaviors [5]. Consequently, it is
conceivable that fluoxeine plus olanzapine treatment is
effective against treatment-resistant depression due to
their combined actions on numerous brain regions and
various interconnected intracellular signaling pathways
that ultimately promote some type of prophylactic effect.
We have previously shown that sub-chronic (i.e., 7 days)
administration of fluoxetine plus olanzapine results in a
significant reduction of weight gain in rats [5]. This find-
ing is of significant interest as fluoxetine and olanzapine
alone have distinct and opposite effects on body weight
dynamics in both rodents and humans. For example
fluoxetine often reduces food intake and thus body weight
in rats during sub-chronic and chronic (i.e., 21 days) drug
regimens [11], an effect apparently mediated by fluoxet-
ine impact on serotonin (5-HT) signaling pathways [12].
In sharp contrast, treatment with olanzapine is associated
with significant weight gain in schizophrenic patients, a
serious side effect that may increase the risk for type II dia-
betes and may also lead to treatment non-compliance
[13,14]. In this case it is thought that olanzapine's partic-
ular affinity for 5-HT (5-HT2A), dopamine (DA; D2–4), ace-
tylcholine muscarinic (ACh; M1–M5) and histamine (H1)
receptors distributed widely in limbic neural circuits may
somehow account for the pharmacological basis of olan-
zapine-induced weight gain [15]. Needless to say, under-
standing body weight dynamics in relation to drug
augmentation therapy is of critical importance if we are
going to gain further knowledge on the mechanisms of
therapeutic action and side effect profile of anti-depres-
sant medications. In this regard, appetite disturbances are
noted in many medicated depressed patients and several
peptide transmitters implicated in feeding behavior co-
exist in the hypothalamus and may therefore be involved
in the onset of affective states [16]. In this study, we have
examined in more detail the effects of fluoxetine (10 mg/
kg) plus olanzapine treatment on rat body weight during
the time course of 18 days under two olanzapine doses: 5
and 0.5 mg/kg. In addition, we have measured blood lev-
els of these two drugs using gas-chromatography-mass
spectrometry (GC-MS) to assess their combined pharma-
cology and their correlation to body weight dynamics.
Results
All rats tolerated the fluoxetine plus olanzapine regimen
well. There were no mortalities as a result of 18 days of
drug administration in any of the rat groups tested. The
only apparent untoward side effect was tissue necrosis in
the peritoneum of rats injected with fluoxetine plus 5 or
0.5 mg/kg olanzapine (Fig. 1). Thus, fluoxetine appears to
produce focal necrotising vasculitis within the site of injec-
tion. The necrotic properties of the above antidepressant
have previously been reported [17]. Olanzapine, on the
other hand, does not produce tissue necrosis in the peri-
toneal cavities of rats when administered alone (data not
shown).
All rats showed a steady increase in body weight during
the 18 days of cyclodextrin or fluoxetine plus olanzapine
treatment. However, fluoxetine in combination with
olanzapine significantly retarded this growth rate (P ≤
0.001) when compared with the vehicle-treated group
(Fig. 2). This weight loss, beginning on day 7 of treatment,
was observed equally in both the 5 and 0.5 mg/kg olanza-
pine-treated groups. At this time, rats administered with
cyclodextrin showed body weights of 275.6 ± 3.7 g,
whereas fluoxetine plus 5 mg/kg olanzapine-treated ani-
mals showed weights of 248.1 ± 4.4 g (at the 95% confi-
dence interval for differences between means: 13.8 to
41.2, P ≤ 0.001). Along the same lines on day 7, rats
treated with fluoxetine plus 0.5 mg/kg olanzapine showed
body weights of 254.1 ± 3.7 g. In contrast, their vehicle-
treated cohorts showed weights of 277.8 ± 7.3 g (at the
95% confidence interval for differences between means:
6.90 to 40.41, P ≤ 0.01). The magnitude of this difference
in body weight increased further on day 14 and was firmly
established by day 18 of drug augmentation therapy (Fig.
3). Thus, fluoxetine treatment, irrespective of olanzapine's
ability to cause weight gain, produces a gradual and con-
siderable weight loss in male rats. In general, these find-
ings are consistent with mono-therapy studies where
chronic olanzapine treatment invariably leads to weight
loss in rodents [18,19].
The fact that fluoxetine plus olanzapine treatment for 18
days retards the continuous weight gain observed in cyclo-
dextrin-exposed rats suggests at least two testable possibil-
ities. First, rats exposed to drug augmentation therapy
might be eating less than their cyclodextrin-treated
cohorts. Second, administration of fluoxetine plus olan-
zapine might be altering glucose metabolism of drug-
treated animals. To test the first possibility, we measured
average food intake over a 12 hr period of the dark cycleBMC Pharmacology 2004, 4:27 http://www.biomedcentral.com/1471-2210/4/27
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in rats treated with fluoxetine plus 5 mg/kg olanzapine.
On day 10 of drug treatment, rats exposed to this drug
augmentation regimen ate significantly less (t10 = 5.5, P ≤
0.001) than vehicle-treated animals (Fig. 4). Interestingly,
the same group of rats also showed a significant reduction
in water intake (t10 = 6.7, P ≤ 0.01) when compared with
cyclodextrin-treated animals (Fig. 4). Thus, rats exposed
to fluoxetine plus 5 mg/kg olanzapine are eating (~32%)
and drinking (~38%) less at day 10 and 12 of drug treat-
ment, respectively.
In contrast to the above findings, animals injected first
with fluoxetine and then 15 min later with 0.5 mg/kg
olanzapine did not show differences in food (t10 = 2.2, P
≥ 0.05) or water (t10 = -1.2, P ≥ 0.05) consumption during
the dark cycle when compared with cyclodextrin-treated
rats (Fig. 5). Thus, although fluoxetine plus 0.5 mg/kg
olanzapine-treated rats show a significant and progressive
weight loss at days 7, 14 and 18, this weight loss is not
associated with reductions in food or water consumption.
This finding suggests that chronic olanzapine treatment is
apparently modifying feeding behavior in rats, an effect
particularly conspicuous at the 5 mg/kg dose. To test the
second possibility, that chronic fluoxetine plus olanzap-
ine is altering the metabolism of drug-treated animals, we
measured their blood glucose levels under fasting condi-
tions (Fig. 6). Glucose levels at the time of sacrifice were
not significantly different between cyclodextrin- and drug-
treated animals at either the 5 mg/kg olanzapine dose (t10
= -0.73, P ≥ 0.05) or the lower 0.5 mg/kg olanzapine dose
(t10 = -1.4, P ≥ 0.05). Thus, changes in glucose metabolism
are not the proximate cause affecting the differential body
weight dynamics, nor the differential consumption of
food and water among vehicle- and drug-treated rats.
Along the same lines, levels of the hormone leptin did not
differ between cyclodextrin- and drug-treated animals
(data not shown), thus suggesting that chronic fluoxetine
and olanzapine drug therapy does not affect leptin mes-
sages under fasted conditions in male rats.
We next assessed the pharmacokinetic profile of fluoxet-
ine and olanzapine in rats treated with the above drug
Tissue necrosis during chronic fluoxetine (fluox) and olanzapine (olanz) treatment Figure 1
Tissue necrosis during chronic fluoxetine (fluox) and olanzapine (olanz) treatment. This figure depicts equally 
excised peritoneal cavities of males injected IP with either a vehicle-solution (cyclodextrin) or the above drug combination pat-
tern for 18 consecutive days. Note the extent of tissue damage (~1 cm wide) at the site of drug administration. Focal necrosis 
was evident in drug-treated rats irrespective of olanzapine dosing.BMC Pharmacology 2004, 4:27 http://www.biomedcentral.com/1471-2210/4/27
Page 4 of 11
(page number not for citation purposes)
combination pattern (Table 1). At doses of 10 mg/kg and
5 mg/kg respectively, fluoxetine plasma levels ranged
from 62 ng/mL to 476 ng/mL. In contrast norfluoxetine
levels ranged from 292 ng/mL to 1175 ng/mL. Norfluox-
etine is the only identified active metabolite of fluoxetine;
it is formed through N-demethylation of the parent mol-
ecule. Plasma concentrations of olanzapine ranged from
74 ng/mL to 301 ng/mL. At doses of 10 mg/kg fluoxetine
and 0.5 mg/kg olanzapine, levels of the antidepressant
drug ranged from 276 ng/mL to 576 ng/mL, whereas
those for norfluoxetine ranged from 266 ng/mL to 966
ng/mL. Olanzapine levels at this low dose were in the
range of 34 ng/mL and 65 ng/mL. When inter-group com-
parisons of drug plasma concentrations were made
between fluoxetine (10 mg/kg) in combination with olan-
zapine at either the 5 mg/kg or the 0.5 mg/kg dose range,
differences in mean values of the two groups did not vary
enough (P ≥ 0.05) to reject the possibility of random sam-
pling variability. A similar statistical trend was observed
for norfluoxetine levels after 18 consecutive days of drug
treatment; there was not a statistically significant differ-
ence (P ≥ 0.05) between the two groups. However, differ-
ences in the median values between 5 mg/kg and 0.5 mg/
kg olanzapine doses were greater than would be expected
by chance (P ≤ 0.001). As expected, rats injected IP with
cyclodextrin showed no traces of either fluoxetine or olan-
zapine levels in plasma (≤5 ng/mL). In general, our GC-
MS measurements detect pharmacological and relevant
levels of both fluoxetine and olanzapine in rats, a finding
consistent with previous reports [4].
Discussion
The present study shows that 18 days of concomitant
fluoxetine and olanzapine treatment leads to a significant
Body weight changes during chronic fluoxetine (fluox, 10 mg/kg) and olanzapine (olanz, 5 mg/kg) treatment Figure 2
Body weight changes during chronic fluoxetine (fluox, 10 mg/kg) and olanzapine (olanz, 5 mg/kg) treatment. 
Rat body weights were recorded before and after drug augmentation therapy. Data represent means ± SEM. N = 5–7 animals 
per group. *P ≤ 0.05 when compared with drug-treated rats. NS = not significant.BMC Pharmacology 2004, 4:27 http://www.biomedcentral.com/1471-2210/4/27
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decrease of weight gain in rats. Given that the above drug
combination is particularly effective in treatment-resistant
depression, our findings are of interest for revealing
potential liabilities associated with its therapeutic use.
Here, our data suggest a possible pharmacodynamic
event-related effect regarding the action of two psychoac-
tive drugs over time. Indeed, there is a well-established
relationship between clinically effective drugs, appetite
control and weight changes across diverse patient popula-
tions [20]. For instance, weight gain appears to be corre-
lated positively with clinical responses to anti-psychotic
medication [21,22]. The combination of fluoxetine and
olanzapine in our studies produced weight loss irrespec-
tive of anti-psychotic drug dosing. That is, fluoxetine at a
fixed dose of 10 mg/kg administered concomitantly with
either 5 mg/kg or 0.5 mg/kg olanzapine yielded an
approximately 20% mean reduction in body weight for
both doses. Therefore, body weight changes associated
with the above drug combination are more likely due to
the effects of olanzapine or its metabolic pathways (see
below). Indeed, this hypothesis is further supported by
the fact that although rats treated with 5 mg/kg olanzap-
ine were eating and drinking less than animals injected
with a smaller dose (i.e., 0.5 mg/kg), body weight out-
come was nevertheless similar for all drug-treated rats. In
this regard, it is conceivable that the suppressed consump-
tion of food and water observed in animals injected IP
with 5 mg/kg olanzapine might have been the result of
malaise, or at least the result of aversion to the hedonic
aspects of food and water. However this possibility does
not explain, in general, the sustained and consistent
decrease in weight gain for all rats treated with fluoxetine
and olanzapine. Changes in glucose metabolism were
also ruled out as a causal role for the reduction in weight
gain and food intake as both vehicle-and drug-treated ani-
mals showed undistinguishable serum glucose levels dur-
ing fasting. Further studies of these questions will yield
Changes in food and water intake during chronic fluoxetine (fluox, 10 mg/kg) and olanzapine (olanz, 5 mg/kg) treatment Figure 3
Changes in food and water intake during chronic fluoxetine (fluox, 10 mg/kg) and olanzapine (olanz, 5 mg/kg) 
treatment. Rats under this combined drug regimen showed a significant reduction in the consumption of nutrients and fluids 
at day 10 and 12 of drug therapy, respectively. Data represent means ± SEM. N = 5–7 animals per group. *P ≤ 0.05 when com-
pared with drug-treated rats.BMC Pharmacology 2004, 4:27 http://www.biomedcentral.com/1471-2210/4/27
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insight into centrally acting peptides and/or peripherally
acting thermogenic mechanisms underlying decreases in
weight gain in adult rats.
Placing our results in the framework of clinical situations,
decreases in rat weight gain as a result of fluoxetine and
olanzapine treatment do not mirror the profile occurring
across diverse patient populations. There is evidence that
long-term fluoxetine plus olanzapine treatment fre-
quently leads to weight gain in individuals with major
depressive disorders with and without treatment-resistant
depression [23]. Further, high doses of fluoxetine do not
appear to counteract the weight gain often induced by
atypical anti-psychotics such as olanzapine [24]. The stark
disparity between rat and human studies regarding body
weight dynamics raises the possibility of mismatched
models for revealing certain liabilities associated with
fluoxetine and olanzapine therapy in mood disorders. It is
conceivable, for instance, that rats might be more sensi-
tive to the anorectic effects of fluoxetine than humans.
Fluoxetine is known to produce anorectic effects that
often lead to a decrease in weight gain; a phenomenon
observed equally at the experimental and clinical level
[11,25,26]. Alternatively, olanzapine metabolism may
differ significantly in rats as indirectly suggested by previ-
ous reports [27,28]. In this context, olanzapine is metab-
olized to its 10- and 4'-N-glucuronides, with the 10-N-
glucuronide being the most abundant metabolite in
humans [15,29]. As the pharmacokinetic and pharmaco-
dynamic profile of olanzapine in rats is relatively obscure
[27], it is possible that changes in glucuronidation metab-
olism in rodents may have impacted the ability of the par-
ent drug to influence heterogeneous population of cells
associated with body weight dynamics. From these state-
ments, one might conclude that our findings are not clin-
ically significant and perhaps of limited value for
Body weight changes during chronic fluoxetine (fluox, 10 mg/kg) and olanzapine (olanz, 0.5 mg/kg) treatment Figure 4
Body weight changes during chronic fluoxetine (fluox, 10 mg/kg) and olanzapine (olanz, 0.5 mg/kg) treatment. 
Rat body weights were recorded before and after drug augmentation therapy. Data represent means ± SEM. N = 5–7 animals 
per group. *P ≤ 0.05 when compared with drug-treated rats. NS = not significant.BMC Pharmacology 2004, 4:27 http://www.biomedcentral.com/1471-2210/4/27
Page 7 of 11
(page number not for citation purposes)
additional investigation. Although the animal data
indeed do not support the clinical situation, the above
findings could harbor important information as to how
species-specific differences limit drug-drug interactions or
body weigh regulation, lessons that could influence sub-
sequent studies regarding fluoxetine and olanzapine ther-
apy in more defined experimental settings.
In the present study, measurements of fluoxetine, nor-
fluoxetine and olanzapine plasma concentrations were
made to assess their pharmacology after 18 days of com-
bined drug exposure. In general, drug plasma levels fell
within the expected therapeutic range typically observed
in psychiatric patients. For instance, after 30 days of dos-
ing at 40 mg/day, plasma levels of fluoxetine are in the
range of 90–300 ng/mL across diverse patient populations
[15]. In our animal studies, at a dose of 10 mg/kg (IP),
mean plasma concentrations achieved were in the range
of 300–400 ng/mL after 18 days of combined drug treat-
ment. Oral doses of olanzapine at 20 mg/day often yield
plasma levels of 20–100 ng/mL in healthy volunteers and
in patients with schizophrenia [30]. Concentrations ≥80
ng/mL are considered threshold for the occurrence of
adverse effects. In our present study, at a dose of 5 mg/kg
olanzapine, mean plasma levels achieved of the anti-psy-
chotic drug were ~178 ng/mL. The relatively high levels of
olanzapine may help explain in part the hypophagic and
adipsic phenomena experienced by rats at this particular
dosing. Interpreted in this way, olanzapine concentra-
tions ≥80 ng/mL (as in our studies) reached a threshold
for the onset of malaise or taste aversion effects. In con-
trast, animals exposed to a 0.5 mg/kg olanzapine dose
showed optimal therapeutic range of olanzapine plasma
levels (~47 ng/mL) and normal feeding and drinking
behaviors. It should be noted that the dosing paradigm
implemented in our current studies yielded fluoxetine,
norfluoxetine and olanzapine plasma concentrations sim-
ilar to those reported by Zhang et al [4] under an acute
experimental design. Therefore it is possible that little or
no significant metabolic interactions between fluoxetine
and olanzapine combination treatment occurs in rats as a
function of chronic drug exposure. This possibility has
No changes in food consumption or water intake during chronic fluoxetine (fluox, 10 mg/kg) and olanzapine (olanz, 0.5 mg/kg  treatment Figure 5
No changes in food consumption or water intake during chronic fluoxetine (fluox, 10 mg/kg) and olanzapine 
(olanz, 0.5 mg/kg) treatment. Rats under this combined drug regimen did not show an apparent reduction in the con-
sumption of nutrients and fluids at day 10 and 12 of drug therapy, respectively. Data represent means ± SEM. N = 5–7 animals 
per group. NS = not significant.BMC Pharmacology 2004, 4:27 http://www.biomedcentral.com/1471-2210/4/27
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No changes in fasting glucose levels after chronic fluoxetine (fluox, 10 mg/kg) and olanzapine (olanz, 5 mg/g or 0.5 mg/kg)  dosing Figure 6
No changes in fasting glucose levels after chronic fluoxetine (fluox, 10 mg/kg) and olanzapine (olanz, 5 mg/g or 
0.5 mg/kg) dosing. Rats under the depicted drug regimens did not show overt differences in glucose metabolism. Data rep-
resent means ± SEM. N = 5–7 animals per group. NS = not significant. Non-fasting glucose levels in rats are typically in the 
range of 155–242 mg/dL.
Table 1: Plasma concentrations of fluoxetine, norfluoxetine and olanzapine after 18 consecutive days of drug augmentation therapy.
Drug Measured Fluoxetine Dose (10 mg/kg) Olanzapine Dose (5 mg/kg)
Fluoxetine 344.1 ± 54.2 (ng/mL)
Norfluoxetine 695.4 ± 118.4 (ng/mL)
Olanzapine 178.5 ± 34 (ng/mL)*
Drug Measured Fluoxetine Dose (10 mg/kg) Olanzapine Dose (0.5 mg/kg)
Fluoxetine 410.0 ± 36.6 (ng/mL)
Norfluoxetine 501.5 ± 114.7 (ng/mL)
Olanzapine 46.7 ± 4.4 (ng/mL)
The fact that regardless of olanzapine dosing both rat groups lost equal amounts of body weight is indicative that these two phenomena (i.e., 
relative drug levels and body weight dynamics) may not be causally related. No discernible changes in brain structure or integrity were found, as 
assessed by Nissl staining and stereological cell counts conducted within the rat hypothalamus (data not shown). Values are means ± SEM. N = 7 
per dosing group. * P ≤ 0.01 when compared with appropriate olanzapine dose.BMC Pharmacology 2004, 4:27 http://www.biomedcentral.com/1471-2210/4/27
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merit as no clinically significant metabolic interactions
are also reported during combined fluoxetine and olanza-
pine therapy [29]. Placing the current data in the frame-
work of the growing body of experimental and clinical
evidence, it is unlikely that drug-drug interactions modify
the pharmacological profile of fluoxetine and olanzapine
when the two psychoactive agents are administered con-
comitantly to experimental animal models.
Conclusions
Combination therapies of anti-depressant and anti-psy-
chotic drugs are increasingly used for treatment-resistant
mood disorders. Here, we have provided further evidence
that fluoxetine and olanzapine have pharmacodynamic
event-related effects on body weight dynamics [5]. In rats,
these effects are manifested in the form of anorexia or per-
haps anhedonia to food and water. Of interest, anorectic
phenomena are also observed in rats chronically treated
with valproic acid and lithium [31]; both valproic acid
and lithium are widely touted as effective prophylactic
agents for manic-depressive illness [32]. It is quite proba-
ble therefore that augmentation therapy of several mood
stabilizers is associated with weight loss in rats, whereas
the same combination drug pattern results in weight gain
in special patient populations. This disparity adds a new
level of complexity to the issue of body weight changes
associated with psychopharmacology [19], and indicates
species-specific variations in this phenomenon. In our
particular case, adjusting olanzapine dosing to rat studies
from 5 mg/kg to 0.5 mg/kg should preclude malaise bouts
and/or taste aversion effects. In addition, the above dos-
age modification should be considered for achieving clin-
ically therapeutic anti-psychotic plasma levels. If such a
dosing paradigm is overlooked, it may lead to erroneous
conclusions regarding mechanisms of medication action
and side effect profile during drug augmentation therapy.
Methods
Animals and drug administration
Adult male Long-Evans rats (Harlan, Indianapolis, IN)
were used in all experiments described herein. Prior to any
drug treatment, all rats were handled for 5 days to mini-
mize non-specific stress. Rats were then randomly
assigned to the various experimental groups and cage
mates received the same drug treatment. Animals were
group-housed, 2–3 per cage under a 12 hr light:dark cycle
(light on 0700) and allowed ad libitum access to food and
water, except when noted (see below). For the chronic
drug regimen, rats were injected intraperitoneally (IP) first
with fluoxetine (10 mg/kg) followed 15 min later by olan-
zapine (5 or 0.5 mg/kg) to decrease potential pharmacok-
inetic interactions. Fluoxetine was dissolved in 5% γ-
cyclodextrin, whereas olanzapine was dissolved in 12% γ-
cyclodextrin (cyclodextrin was used to improve the stabil-
ity and bioavailability of poorly soluble drugs). Dosages
of the two drugs were chosen according to each drug's in
vivo potencies for affecting 5-HT, DA, ACh and H systems
[15,33,34], and also from pharmacological doses
reported in the literature [4,8,11,35,36]. Doses of drugs
are expressed as their respective salts. Control animals
received 5% and 12% γ-cyclodextrin injections (1 ml/kg)
at 15 min intervals so that this group was given the vehi-
cle-solution at the same times as the fluoxetine plus olan-
zapine experimental group. All injections were
administered between 1000 and 1100 hr of the light cycle.
All aspects of the following experiments were carried out
in accordance with the NIH Guide for the Care and Use of
Laboratory Animals and with approval from the NYIT
IACUC.
Experimental procedures
Rats were injected with fluoxetine plus olanzapine or their
respective vehicle-solutions for 18 consecutive days and
body weights recorded before (day 0) and after (day 18)
drug treatment. In addition, body weights were also
recorded 7 and 14 days after drug treatment to adjust for
dosage. To determine average food intake over a 12 hr
period, control-vehicle and experimental rats were given
pre-measured food pellets (25 g/rat) on day 10 and subse-
quent consumption was recorded on the next day. To
keep track of food spillage, cage bedding was randomly
separated to assess degree of unconsumed food. A similar
procedure was instituted to assess average water intake
over a 12 hr period: both groups were given pre-measured
tap water (100 mL/rat) on day 12 and subsequent con-
sumption was recorded on the next day. On the last day of
injections (day 18), rats were either decapitated or
perfused under deep chemical anesthesia (ketamine/xyla-
zine/acepromazine, 60 mg/kg) with 4%
paraformaldehyde. Trunk blood or blood collected from
cardiac puncture was collected in centrifuge tubes con-
taining either no EDTA or a 0.3 M EDTA (pH 7.4) solu-
tion. Blood samples with 0.3 M EDTA were centrifuged at
10,000 RPM for 10 min and the collected serum frozen at
-80°C until determination of glucose levels. Blood col-
lected without EDTA was also frozen at -80°C until deter-
mination of drug plasma concentrations by GC-MS.
Glucose measurements
To determine relative glucose levels, all animals were
fasted for 12 hr on the last day of injections (i.e., day 18).
Glucose serum levels were determined using the Life-Scan
One Touch Basic Meter (Johnson & Johnson, New Bruns-
wick, NJ). In brief, 10 µl of serum was pipetted as a free-
flowing drop onto each One Touch Test Strip and read in
the glucose meter for 45 sec. Fasting glucose levels are pre-
sented as means ± SEM in mg/dL.BMC Pharmacology 2004, 4:27 http://www.biomedcentral.com/1471-2210/4/27
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Analysis for fluoxetine, norfluoxetine and olanzapine by 
GC-MS
All solvents used for drug analyses were HPLC grade.
Chloroform and 1-chlorobutane were obtained from
Burdick & Jackson (Muskegon, MI). Ethyl Acetate and ace-
tonitrile were obtained from EMD (Gibbstown, NJ).
Ammonium Hydroxide, ACS certified, was obtained from
Fisher (Fairlawn, NJ). Ascorbic acid was obtained from
Sigma (St. Louis, MO), whereas trifluoroacetic anhydride
was obtained from Pierce (Rockford, IL).
Working solutions containing olanzapine, fluoxetine and
norfluoxetine at 10 ng/µL, 1.0 ng/µL, and 0.1 ng/µL,
respectively were prepared in methanol. The working
solutions used to prepare the calibration standards and
controls were derived from different sources of reference
material (e.g., fluoxetine) or different weighing of the
same reference material (e.g., olanzapine). Calibration
standards and controls were prepared by adding appropri-
ate amounts of working solutions to clean, separate silan-
ized 16 × 100 mm culture tubes that contained 1 mL of
blank bovine blood and 0.2 mL of 2.5% ascorbic acid. The
calibration standards ranged from 1 ng/mL to 1000 ng/
mL. The controls were prepared at 35 ng/mL, 100 ng/mL,
and 650 ng/mL.
A 0.25 mL volume of each blood sample was transferred
to clean silanized 16 × 100 mm culture tubes. To bring the
sample preparation to a volume of 1 mL, a 0.75 mL vol-
ume of Milli Q H2O was added to each tube. The samples
were therefore a 4-fold dilution compared with the stand-
ards and controls. A 0.2 mL volume of 2.5% ascorbic acid
was added to each sample in a preparation tube. Sample,
standards, and controls were extracted by a liquid/liquid
procedure. Eighty ng of fluoxetine-d6 (80 µL of 1 ng/µL
fluoxetine-d6 in Milli Q H2O) and 80 ng of clozapine (80
µL of 1 ng/µL clozapine in methanol) were added to each
tube and the tubes were then briefly vortexed. A 0.1 mL
volume of the concentrated ammonium hydroxide and a
4 mL volume of 1-chlorobutane: acetonitrile (4:1) was
then added to each tube. A clean teflon-lined screw cap
was placed on each tube. The tubes were mixed 20 min
using a reciprocating shaker and centrifuged at 2000 rpm
for 10 min using an IEC centrifuge (Needham, MA). Using
clean, separate glass Pasteur pipettes, the upper organic
layer from each tube was transferred to clean, separate 13
× 100 mm culture tubes. The organic layer was evaporated
to dryness under a stream of air at 40°C using a Turbo Vap
evaporator (Zymark Corporation, Hopkinton, MA).
For derivatization, a 0.1 mL volume of chloroform and a
0.1 mL volume of trifluoroacetic anhydride were added to
each tube. Clean teflon-lined screw caps were then placed
on each tube. The tubes were heated for 20 min at 70°C
using a dry block heater. After heating, the tubes were
removed from the heater and allowed to cool at room
temperature. The caps were then removed and the tubes
evaporated using the same conditions as described above.
Derivatized extracts were reconstituted with 100 µL of
ethyl acetate and were then transferred to clean, separate
auto-sampler vials.
The GC-MS system consisted of an Agilent 6890 gas chro-
matograph and an Agilent 5973 MSD mass spectrometer
(Palo Alto, CA). The data system consisted of a Hewlett-
Packard X A 6/400 computer and Agilent Chemstation
software. For chromatographic separation, a ZB-5, 30
meter × 0.25 mm id, 0.25 µm capillary column (Phenom-
enex, Torrance, CA) was used. The carrier gas was ultra
high purity helium at a flow rate of 1.0 mL/min. The injec-
tion port temperature was 260°C and the transfer line
temperature was 300°C. The column oven temperature
program was 125°C, held at this temperature for 0.2 min,
and then increased to 300°C. Positive chemical ioniza-
tion was used for the mass spectrometry analysis. The ion
source temperature was 200°C and ammonia was used as
a reagent gas. Selected ion monitoring was used and the
following ions (m/z) were analyzed: norfluoxetine: 409,
fluoxetine: 423, fluoxetine-d6: 429, olanzapine: 409, cloz-
apine: 423. For fluoxetine, norfluoxetine, and fluoxetine-
d6, the protonated ammonia adducts of the molecule ions
were monitored. For olanzapine and clozapine, the proto-
nated molecule ions were also monitored. Fluoxetine-d6
was used as the internal standard for fluoxetine and nor-
fluoxetine. Clozapine was used as the internal standard
for olanzapine. The limit of quantification for fluoxetine,
norfluoxetine and olanzapine was 5 ng/mL. Data are pre-
sented as the means ± SEM.
Data analysis
Statistical comparisons in body weight and glucose levels
were carried out using one-way ANOVA or two-tailed t
tests where appropriate. Plasma levels of fluoxetine and
olanzapine were analyzed by a Student's t-test. The prob-
ability level interpreted as significant was P ≤ 0.05.
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